Literature DB >> 24687413

The role of polymorphisms of genes CXCL12/CXCR4 and MIF in the risk development IBD the Polish population.

Jerzy Mrowicki1, Karolina Przybylowska-Sygut, Lukasz Dziki, Andrzej Sygut, Jan Chojnacki, Adam Dziki, Ireneusz Majsterek.   

Abstract

Inflammatory bowel disease (IBD) are characterized recurrent inflammation of gastrointestinal tract. The etiology and pathogenesis this disease is currently unclear, but it has become evident that immune and genetic factors are involved in this process. The aim of this study was to determine whether gene polymorphisms: MIF-173 G/C; CXCL12-801 G/A and CXCR4 C/T exon 2 position of rs2228014 is associated with susceptibility to IBD. A total of 286 patients were examined with IBD, including 152 patients with ulcerative colitis and 134 with Crohn's disease (CD) and 220 healthy subjects were recruited from the Polish population. Genotyping for polymorphisms in CXCL12/CXCR4 and MIF was performed by RFLP-PCR. Statistical significance was found for polymorphisms CXCR4, a receptor gene for CXCL12 genotypes and alleles in CD and for genotype C/T and T allele in ulcerative colitis with respect to control. This confirms the effect of CXCL12 gene. The interplay between CXCL12 and its receptor CXCR4 affects homeostasis and inflammation in the intestinal mucosa. Three-gene analysis in CD confirmed the association of genotype GGGGCT. Statistical analysis of clinical data of patients with ulcerative colitis showed significant differences in the distribution of genotype C/T and T allele for CXCR4 in the left-side colitis. Having CXCR4/CXCL12 chemokine axis polymorphisms may predispose to the development of IBD. Activation can also be their defensive reaction to the long-lasting inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687413     DOI: 10.1007/s11033-014-3335-y

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  44 in total

1.  Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease.

Authors:  Julia Dambacher; Tanja Staudinger; Julia Seiderer; Zeljka Sisic; Fabian Schnitzler; Simone Pfennig; Katrin Hofbauer; Astrid Konrad; Cornelia Tillack; Jan-Michel Otte; Joachim Diebold; Burkhard Göke; Thomas Ochsenkühn; Peter Lohse; Stephan Brand
Journal:  Inflamm Bowel Dis       Date:  2007-01       Impact factor: 5.325

2.  Development of chronic colitis is dependent on the cytokine MIF.

Authors:  Y P de Jong; A C Abadia-Molina; A R Satoskar; K Clarke; S T Rietdijk; W A Faubion; E Mizoguchi; C N Metz; M Alsahli; T ten Hove; A C Keates; J B Lubetsky; R J Farrell; P Michetti; S J van Deventer; E Lolis; J R David; A K Bhan; C Terhorst; M A Sahli
Journal:  Nat Immunol       Date:  2001-11       Impact factor: 25.606

3.  Inhibitory effects of anti-CXCR4 antibodies on human colon cancer cells.

Authors:  Alessandro Ottaiano; Antonella di Palma; Maria Napolitano; Carmen Pisano; Sandro Pignata; Fabiana Tatangelo; Gerardo Botti; Angela Maria Acquaviva; Giuseppe Castello; Paolo Antonio Ascierto; Rosario Vincenzo Iaffaioli; Stefania Scala
Journal:  Cancer Immunol Immunother       Date:  2004-12-11       Impact factor: 6.968

4.  Macrophage migration inhibitory factor in the sera and at the colonic mucosa in patients with ulcerative colitis: clinical implications and pathogenic significance.

Authors:  H Murakami; S M Akbar; H Matsui; M Onji
Journal:  Eur J Clin Invest       Date:  2001-04       Impact factor: 4.686

5.  Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma.

Authors:  Mahboobeh Razmkhah; Abdul-Rasoul Talei; Mehrnoosh Doroudchi; Tahereh Khalili-Azad; Abbas Ghaderi
Journal:  Cancer Lett       Date:  2004-12-13       Impact factor: 8.679

6.  CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system.

Authors:  Iris Dotan; Lael Werner; Sharon Vigodman; Sigal Weiss; Eli Brazowski; Nitsan Maharshak; Ofer Chen; Hagit Tulchinsky; Zamir Halpern; Hanan Guzner-Gur
Journal:  Inflamm Bowel Dis       Date:  2010-04       Impact factor: 5.325

7.  Amelioration of dextran sulfate sodium-induced colitis by anti-macrophage migration inhibitory factor antibody in mice.

Authors:  Tatsuya Ohkawara; Jun Nishihira; Hiroshi Takeda; Shuhei Hige; Mototsugu Kato; Toshiro Sugiyama; Toshihiko Iwanaga; Hideki Nakamura; Yuka Mizue; Masahiro Asaka
Journal:  Gastroenterology       Date:  2002-07       Impact factor: 22.682

Review 8.  Pediatric inflammatory bowel disease: is it different?

Authors:  Arie Levine
Journal:  Dig Dis       Date:  2009-09-24       Impact factor: 2.404

9.  Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus.

Authors:  Ori Wald; Orit Pappo; Rifaat Safadi; Michal Dagan-Berger; Katia Beider; Hanna Wald; Suzanna Franitza; Ido Weiss; Shani Avniel; Pal Boaz; Jacob Hanna; Gidi Zamir; Ahmed Eid; Ofer Mandelboim; Ulrich Spengler; Eithan Galun; Amnon Peled
Journal:  Eur J Immunol       Date:  2004-04       Impact factor: 5.532

10.  Association of MIF-173 gene polymorphism with inflammatory bowel disease in Chinese Han population.

Authors:  Bao-Ying Fei; Huo-Xiang Lv; Jiang-Min Yang; Zai-Yuan Ye
Journal:  Cytokine       Date:  2007-11-28       Impact factor: 3.861

View more
  7 in total

Review 1.  Emerging significance of NLRs in inflammatory bowel disease.

Authors:  Beckley K Davis; Casandra Philipson; Raquel Hontecillas; Kristin Eden; Josep Bassaganya-Riera; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2014-12       Impact factor: 5.325

2.  The left-right Pitx2 pathway drives organ-specific arterial and lymphatic development in the intestine.

Authors:  Aparna Mahadevan; Ian C Welsh; Aravind Sivakumar; David W Gludish; Abigail R Shilvock; Drew M Noden; David Huss; Rusty Lansford; Natasza A Kurpios
Journal:  Dev Cell       Date:  2014-12-04       Impact factor: 12.270

Review 3.  Emerging Roles for Noncanonical NF-κB Signaling in the Modulation of Inflammatory Bowel Disease Pathobiology.

Authors:  Dylan K McDaniel; Kristin Eden; Veronica M Ringel; Irving C Allen
Journal:  Inflamm Bowel Dis       Date:  2016-09       Impact factor: 5.325

4.  CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.

Authors:  S Matsusaka; S Cao; D L Hanna; Y Sunakawa; M Ueno; N Mizunuma; W Zhang; D Yang; Y Ning; S Stintzing; A Sebio; S Stremitzer; S Yamauchi; A Parekh; S Okazaki; M D Berger; R El-Khoueiry; A Mendez; W Ichikawa; F Loupakis; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

5.  Meta-analysis of macrophage migration inhibitory factor (MIF) gene -173G/C polymorphism and inflammatory bowel disease (IBD) risk.

Authors:  Jianfeng Yang; Yanqi Li; Xiaofeng Zhang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

Review 6.  The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.

Authors:  Eva M García-Cuesta; César A Santiago; Jesús Vallejo-Díaz; Yasmina Juarranz; José Miguel Rodríguez-Frade; Mario Mellado
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-27       Impact factor: 5.555

7.  Interleukin-37 Attenuates Lipopolysaccharide (LPS)-Induced Neonatal Acute Respiratory Distress Syndrome in Young Mice via Inhibition of Inflammation and Cell Apoptosis.

Authors:  Bo Li; Xianqiu Ji; Fang Tian; Jingjing Gong; Jie Zhang; Ting Liu
Journal:  Med Sci Monit       Date:  2020-03-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.